Inclusion Criteria:

- Patients ≥ 18 years

- Histologically-proven, locally advanced, or metastatic STS (excluding extraosseus
Ewing sarcoma)

- Patients not amenable to surgery, radiotherapy, or combined-modality therapy with
curative intent

- Patients untreated or previously treated with one or more systemic regimen

- ECOG Performance status 0-2 (Appendix A)

- At least one untreated (not previously irradiated) target lesion that could be
measured in one dimension, according to RECIST criteria

- A life expectancy of 12 weeks or more

- Adequate baseline bone marrow, hepatic and renal function, defined as follows:

- Neutrophils > 1.5 x 109/L and platelets > 100 x 109/L

- Bilirubin < 1.5 x ULN

- AST and/or ALT < 2.5 x ULN in absence of liver metastasis or < 5 x ULN in
presence of liver metastasis

- Serum creatinine < 1.5 x ULN

- Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50
ml/min

- Patients may have had prior treatment providing the following conditions are met
before treatment start:

- Surgery and radiation therapy: wash-out period of 14 days

- Systemic therapy: wash-out period of 21 days

- Patients must give written informed consent

Exclusion Criteria:

- Patients may not receive any other investigational agents while on study

- Patients with myocardial infarction within the last six (6) months, unstable angina,
New York Heart Association (NYHA) grade II or greater congestive heart failure, or
serious cardiac arrhythmia requiring medication

- LVEF < 55% (only for patients candidate for doxorubicin treatment)

- Uncontrolled hypertension

- Prolonged QTc interval (congenital or acquired) > 450 ms

- History or evidence upon physical examination of CNS disease unless adequately
treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with
standard medical therapy) or history of stroke

- Patients with active or uncontrolled systemic disease/infections or with serious
illness or medical conditions, which is incompatible with the protocol

- Known hypersensitivity/allergic reaction or contraindications to human albumin
preparations or to any of the excipients

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol

- Pregnancy or lactation. Patients - both males and females - with reproductive
potential (i.e. menopausal for less than 1-year and not surgically sterilized) must
practice effective contraceptive measures throughout the study. Women of
child-bearing potential must provide a negative pregnancy test (serum or urine)
within 14 days prior to registration